SEO URLwww.firestrike.ai/deals/arcellx-gilead-sciences-acquisition-2026-7
acquisitionAnnounced · Feb 23, 2026BiotechnologySource · CredibleArticle · Factual
Gilead Sciences acquires Arcellx
David Najork · Founding Software Engineer
Published · Updated · 1 min read
Deal value
$7.8B
Target
Arcellx
NASDAQ: ACLX · Redwood City, California
Acquirer
Gilead Sciences
Full Acquisition
Status
Pending
Gilead Sciences agreed to acquire Arcellx. Reported deal value: $7.8B. Status: Pending. Sector: Biotechnology. Target headquarters context: Redwood City, California, United States.
This page summarizes publicly available information about the transaction as of 2026-02-23. Figures and status may change as filings and press coverage update.
ACLX Gilead has agreed to acquire Arcellx in a deal worth $7.8bn , as the drugmaker looks to add a CAR T-cell therapy for blood cancer treatment on the cusp of approval to its portfolio
Deal timeline
Announced
Feb 23, 2026 · finance.yahoo.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Biotechnology with a reported deal value of $7.8B. Figures and status may change as sources update.
Sources: finance.yahoo.com · Primary article · FireStrike proprietary index